当前位置： SCI文献检索 > European Journal of Internal Medicine期刊下所有文献 > Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.

Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.

Abstract：

BACKGROUND:Antithrombotic/anticoagulation effects of direct oral anticoagulants (DOACs) are dose-dependent. However, recent observations suggest that administering lower dose DOACs may better protect against all-cause mortality. We investigated whether, in patients with established atherosclerosis, DOAC dose selection would affect the risk of all-cause mortality. METHODS:We performed a structured literature research for controlled trials allowing random assignment to a lower dose DOAC, a higher dose DOAC, or control therapy in patients with established atherosclerosis. Pooled risk ratios (RRs) of all-cause mortality in lower and higher dose DOACs versus control therapy were estimated using a random-effect model. RESULTS:Atherosclerosis manifested as acute coronary syndrome (n=17,220), stable coronary (CAD) and/or peripheral artery disease (PAD) (n=27,395) or CAD associated with atrial fibrillation (n=4,510). Antithrombotic doses of rivaroxaban (2.5 mg or 5.0 mg BID) or dabigatran (50 mg, 75 mg, 110 mg, or 150 mg, BID) were tested in three trials versus single or dual antiplatelet control therapy, whereas anticoagulation doses of edoxaban (30 mg or 60 OD) were tested versus warfarin in one trial. Compared to control, patients receiving lower dose (RR 0.80, 95% CI 0.73-0.89, p<0.0001, I²=0%), but not those receiving higher dose DOACs (RR 0.95, 95% CI 0.87-1.05, p=0.3074, I²=0%), had a significant reduction of all-cause mortality. Benefit from lower dose DOACs remained after sensitivity analysis or direct comparison with higher dose DOACs (RR 0.84, 95% CI 0.76-0.93, p=0.0009, I²=0%). CONCLUSIONS:Within antithrombotic/anticoagulation regimens of DOAC administration, selection of lower dose appears to protect from all-cause mortality in patients with established atherosclerosis.

journal_name

Eur J Intern Med

journal_title

European journal of internal medicine

authors

Cappato R,Chiarito M,Giustozzi M,Briani M,Ali H,Riva L,Bonitta G,Lodigiani C,Furlanello F,Balla C,Lupo P,Stefanini G

doi

10.1016/j.ejim.2020.09.007

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

14-20

eissn

0953-6205

issn

1879-0828

pii

S0953-6205(20)30353-8

journal_volume

pub_type

杂志文章

在线工具

Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.